NSCLC

IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable

Thomas Wu, Research physician at Genentech, shared a post by  X:

“Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT.

Thanks all investigators from 15 sites in China. It is impossible without their hard works!”

Patrick Forde, Co-Director of Division of Upper Aerodigestive Malignancies at John Hopkins, added:

“Outstanding work from Dr. Thomas Wu and colleagues, leading the next generation of studies in earlier stage lung cancer! I had the pleasure of being a reviewer for this manuscript, highly recommend!”

Source: Thomas Wu/X and Patrick Forde/X

cancer Cancer Cell Genentech John Hopkins Lung cancer NSCLC OncoDaily Oncology Patrick Forde Thomas Wu